AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT00499850
Drug: Leucovorin
RxNorm normalized name: Leucovorin
DrugBank: Leucovorin (DB00650)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: intravenous infusion
Trial: NCT02220296
Drug: Insulin 338
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Healthy subjects will receive a single dose of insulin 338 in ascending doses. Injected subcutaneously (under the skin).
Trial: NCT00002721
Drug: doxorubicin hydrochloride
RxNorm normalized name: Doxorubicin Hydrochloride
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT01231464
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo
Trial: NCT02602353
Drug: Placebo Patch
FDA approved: no
EMA approved: no
PMDA approved: no
Description: One Placebo Patch applied daily for 3 days
Trial: NCT01068405
Drug: Methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Methotrexate: 10mg/week administered in one time, the same day each week (every monday for example)during 12 months
Trial: NCT01971606
Drug: Rosuvastatin
RxNorm normalized name: Rosuvastatin
DrugBank: Rosuvastatin (DB01098)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Patients will be randomized in a ratio of 1:1 to A) High-dose rosuvastatin vs. B) Placebo.~A) Rosuvastatin group : Administration of 40mg of rosuvastatin PO 12 hours before surgery and 20mg of rosuvastatin PO 2hours before surgery and 10mg of rosuvastatin PO daily at postoperative period.~B) Placebo group : Administration of placebo at 12 hours and 2 hours before surgery and 10mg of rosuvastatin PO daily at postoperative period.
Trial: NCT00284869
Drug: LPS
RxNorm normalized name: ALPS LOTION
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02091739
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Solution for injection prepared by reconstitution of powder with 0.9% Sodium Chloride (NaCl).
Trial: NCT00405353
Drug: Androgel 10 grams of gel containing 100 mg of testosterone
RxNorm normalized name: testosterone Topical Gel [Androgel]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: testosterone gel
Trial: NCT03088358
Drug: TeaRx
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01357109
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matched placebo bid
Trial: NCT01566630
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo to RLX030 as intravenous infusion for 72 hours
Trial: NCT01566630
Drug: RLX030
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RLX030 1 mg/mL vials
Trial: NCT03579914
Drug: intravenous Placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients receive intravenous Placebo (saline) injection
Trial: NCT05973318
Drug: Cosopt eye drops, 20 mg/mL + 5 mg/mL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dosing schedule b.i.d.
Trial: NCT00263484
Drug: zoledronic acid
RxNorm normalized name: Zoledronic Acid
DrugBank: Zoledronic acid (DB00399)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: 4 mg, IV (in the vein) on day 1 of each 21 day cycle. 6 Cycles: until progression or unacceptable toxicity develops.
Trial: NCT01421498
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dosage Form: Ophthalmic Solution Frequency: BID Duration: 12 weeks
Trial: NCT01077726
Drug: capecitabine [Xeloda]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1000mg/m2 po bid on days 1-14 of each 3 week cycle
Trial: NCT01016223
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matched placebo swallowed two puffs twice daily
Trial: NCT01108510
Drug: RTV
RxNorm normalized name: Accu-Chek SmartView Test Strips
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ritonavir (RTV) 100 mg tablet administered orally once daily
Trial: NCT01108510
Drug: FTC/TDF
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Emtricitabine (FTC) 200 mg/tenofovir disoproxil fumarate (TDF) 300 mg fixed-dose combination tablet administered orally once daily
Trial: NCT01108510
Drug: COBI placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo to match COBI administered orally once daily
Trial: NCT01108510
Drug: RTV placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo to match RTV administered orally once daily
Trial: NCT03951116
Drug: FCN-437
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FCN-437c is a selective and potent CDK4/6 dual inhibitor, with broad antitumor activity in preclinical pharmacology models, favorable physical and pharmacokinetic (PK) properties, and acceptable toxicity profile in nonclinical studies.
Trial: NCT02156336
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral administration, BID; for a maximum of 51 days.
Trial: NCT03246659
Drug: 111In-CP04 with co-administration of gelofusine/gelaspan
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Radiopharmaceutical preparation with co-administration of gelofusine/gelaspan
Trial: NCT02327273
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00344006
Drug: artemether-lumefantrine
RxNorm normalized name: artemether-lumefantrine
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT04302649
Drug: peritoneal dialysate at 37°C temperature
FDA approved: no
EMA approved: no
PMDA approved: no
Description: during a PET test, patients received peritoneal dialysate warmed at 37°C before infusion
Trial: NCT00113269
Drug: steroids
RxNorm normalized name: CORTICOSTEROIDS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IV and/or oral
Trial: NCT01988298
Drug: Ibuprofen
RxNorm normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Ibuprofen 400 mg each 8 hours
Trial: NCT01988298
Drug: Acetaminophen
RxNorm normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group
Trial: NCT01268124
Drug: HTC-867
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00547053
Drug: Amiloride Solution for Inhalation
RxNorm normalized name: amiloride Oral Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4.5 mL, Amiloride Solution for Inhalation, Inhaled via Omron Ultrasonic Nebulizer, TID, 6 months
Trial: NCT04426084
Drug: Antihypertensive Agents
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pick up of a prescription of C02CA, C02DB02, C03, C07, C08, C09 registered in the Swedish prescribed drug register within 6 month before index date.~Exposures will be studied separately for each antihypertensive class and compared between cases and controls and between cases with different outcomes and controls
Trial: NCT04426084
Drug: Statins (Cardiovascular Agents)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pick up of a prescription of C10AA registered in the Swedish prescribed drug register within 6 month before index date.
Trial: NCT00605995
Drug: Simvastatin
RxNorm normalized name: Simvastatin
DrugBank: Simvastatin (DB00641)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 20 mg taken orally once daily for the first 4 weeks. Dosage will be increased to 40 mg/day at the end of week 4.
Trial: NCT01171183
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT00835510
Drug: Lotrimin Ultra (butenafine) 1%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment applied to affected area twice daily for 7 days
Trial: NCT00350701
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo
Trial: NCT02151357
Drug: DCBCI0901
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DCBCI0901 7.5mg/m2 iv infusion for day 1 to day 5 and day 15 to day 20
Trial: NCT00130507
Drug: Capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT01765296
Drug: Celecoxib
RxNorm normalized name: Celecoxib
DrugBank: Celecoxib (DB00482)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 200 mg capsule
Trial: NCT01765296
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mimic for CG100649 2 mg capsule and for celecoxib 200 mg capsule
Trial: NCT01619852
Drug: .9 normal saline placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administration of .9 normal saline placebo as a bolus and as maintenance throughout the length of the surgical procedure.
Trial: NCT01619852
Drug: Group L (lidocaine)
RxNorm normalized name: lidocaine hydrochloride Injectable Solution [L-Caine]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group L will receive a 1.5 mg/kg bolus of intravenous lidocaine followed by a 2mg/kg/hr infusion that will be started at the time of surgical induction and will be discontinued one hour after the end of the surgical procedure.
Trial: NCT00970489
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Olive Oil capsules
Trial: NCT00394186
Drug: GW427353
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00394186
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00514488
Drug: STI571 (400 mg/day; or 800 mg/day)
RxNorm normalized name: clear days ahead Medicated Pad or Tape
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03090971
Drug: Diclofenac Sodium
RxNorm normalized name: Diclofenac Sodium
DrugBank: Diclofenac (DB00586)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Following microporation, treatment neurofibromas will receive treatment with topical diclofenac
Trial: NCT02331810
Drug: SAR113244
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pharmaceutical form:solution for injection Route of administration: subcutaneous
Trial: NCT02331810
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pharmaceutical form:solution for injection Route of administration: subcutaneous
Trial: NCT04780984
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo comparator
Trial: NCT03416569
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo skin patch + placebo capsule
Trial: NCT00489528
Drug: Somatropin; Recombinant human growth hormone (r hGH)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01011699
Drug: nicotinamide
RxNorm normalized name: Nicotinamide
DrugBank: Nicotinamide (DB02701)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Titration phase of nicotinamide (Nicobion) with the aim of phosphatemia control in 4 weeks with stable dose of calcic carbonate;~Increase of nicotinamide dose of Nicobion 500mg (nicotinamide 500mg), up to 4 tablets daily, as follows:~0 morning, 1 noon, 0 evening (first week), then, 0 morning, 1 noon, 1 evening (second week), then, 1 morning, 1 noon, 1 evening (third week), then, 1 morning, 2 noon, 1 evening (fourth week).
Trial: NCT04338906
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Instead of Camostat Mesilate, tid, d1-d7
Trial: NCT01159223
Drug: ATV/r
FDA approved: no
EMA approved: no
PMDA approved: no
Description: All participants will be randomized to take ATV/r 200 mg/100 mg OD or ATV/r 300/100 mg OD. NRTIs background regimens will remain unchanged if possible. NRTIs background may include zidovudine/lamivudine, zidovudine plus ddI, ddI plus lamivudine, tenofovir plus lamivudine, tenofovir/emtricitabine, zidovudine plus tenofovir. NRTI backbone could be switched or modified due to toxicity or intolerance
Trial: NCT02289989
Drug: Hydrocortisone
RxNorm normalized name: Hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: An experimental cream will be applied to one of the arms of the patient which will be an oregano extract and will be compared to the standard treatment which will be hydrocortisone 1% ointment
Trial: NCT00548067
Drug: Valsartan/hydrochlorothiazide (HCTZ)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02424019
Drug: ILUVIEN 0.19 MG
RxNorm normalized name: Iluvien 0.19 MG Drug Implant
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02235701
Drug: 170 mg/m2 aldoxorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: administered at 170 mg/m2 plus 1 gm/m2/day ifosfamide by continuous intravenous infusion for up to 14 days on Day 1 every 28 days
Trial: NCT02235701
Drug: 250 mg/m2 aldoxorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: administered at 250 mg/m2 plus 1 gm/m2/day ifosfamide by continuous intravenous infusion for up to 14 days on Day 1 every 28 days
Trial: NCT01597505
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo for Surotomycin over-encapsulated tablet administered orally, twice daily for 10 days
Trial: NCT00624715
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo: Small amount of ethanol IV (in the vein), (quarter teaspoon).
Trial: NCT03716622
Drug: Clarithromycin
RxNorm normalized name: Clarithromycin
DrugBank: Clarithromycin (DB01211)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: bismuth-clarithromycin-containing quadruple regimens
Trial: NCT00185510
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 days a week Vehicle (Advabase)
Trial: NCT01967264
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo tablets
Trial: NCT04000932
Drug: Local steroid injection-Diprospan ®, Schering Plough
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The local steroid injection ((1 ml Diprospan ®, Schering Plough containing 6.43 mg of betamethasone dipropionate and 2.63 mg of betamethasone sodium phosphate) will be performed once into the carpal tunnel.1 ml Diprospan ®, Schering Plough extract will be injected by using 23 gauge needle from the distal wrist line through the carpal tunnel only once.
Trial: NCT04658186
Drug: UCB0599
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Drug: UCB0599 Pharmaceutical form: Granules in capsules Route of administration: Oral use Participants will receive UCB0599 in a pre-specified sequence during the Treatment Period.
Trial: NCT00006656
Drug: carmustine in ethanol
RxNorm normalized name: Carmustine
DrugBank: Carmustine (DB00262)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT04658186
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Drug: Placebo Pharmaceutical form: Capsules Route of administration: Oral use Participants will receive Placebo in a pre-specified sequence during the Treatment Period.
Trial: NCT01955759
Drug: rosuvastatin 20 mg tab x1
RxNorm normalized name: rosuvastatin 20 MG
DrugBank: Rosuvastatin (DB01098)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: starting 7 days before coronary by-pass surgery
Trial: NCT00384865
Drug: Simvastatin
RxNorm normalized name: Simvastatin
DrugBank: Simvastatin (DB00641)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Simvastatin 40 mg, taken orally, once a day for 6 months
Trial: NCT03216902
Drug: Vehicle of DE-126 Ophthalmic Solution, high dose of DE-126 Ophthalmic Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vehicle of DE-126 Ophthalmic Solution dosed once daily for 6weeks, followed by high dose of DE-126 dosed once daily for 6 additional weeks
Trial: NCT02960945
Drug: CTP-543, 16 mg (2 x 8 mg tablet)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00867178
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV
Trial: NCT00852670
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching placebo capsules administered orally once daily
Trial: NCT01452737
Drug: Standard Bowel Prep
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects will be asked to take 4L of Golytely the day prior to procedure.
Trial: NCT00994773
Drug: Simvastatin
RxNorm normalized name: Simvastatin
DrugBank: Simvastatin (DB00641)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: daily doses for 14 days
Trial: NCT01522703
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alfalfa Sprouts
Trial: NCT02525081
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: up to 10 mg
Trial: NCT01755546
Drug: EN3409
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Open-Label Buprenorphine HCI Buccal Film at doses 300-900 mcg twice daily
Trial: NCT00601003
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 250 mg/m2/dose in normal saline, IV, infused over 30 minutes on days 1-5 of each cycle.
Trial: NCT01589562
Drug: DW-ES(B) 625mg/5ml
RxNorm normalized name: erythromycin
DrugBank: Erythromycin (DB00199)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Megestrol acetate 625mg/5ml, Nano suspension, Single dose
Trial: NCT02430363
Drug: MK - 3475
RxNorm normalized name: vitamin MK 7
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered Intravenously
Trial: NCT04234945
Drug: Doxycycline Capsule
RxNorm normalized name: Doxycycline Capsules
DrugBank: Doxycycline (DB00254)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Group A will be the study group and will be given oral Doxycycline capsule 100mg bd for 3/7. She will be instructed to commence the medication on day 7 of her next menstrual cycle and hysterosalpingogram will be done within the proliferative phase (Day 10) of the same menstrual cycle after cessation of bleeding.
Trial: NCT04234945
Drug: Multivitamins W/Iron Tab
RxNorm normalized name: MULTIVITAMINS W/IRON TAB
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group B will be the study group and will be given oral Multivitamin capsule i bd for 3/7. She will be instructed to commence the medication on day 7 of her next menstrual cycle and hysterosalpingogram will be done within the proliferative phase (Day 10) of the same menstrual cycle after cessation of bleeding
Trial: NCT00977769
Drug: placebo (NaCl)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hemodynamic effect of
Trial: NCT02724293
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: patients received placebo
Trial: NCT00890539
Drug: Methacholine challenge
RxNorm normalized name: Methacholine Challenge Kit
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clinical and research test used in asthma
Trial: NCT01257399
Drug: Asacol®
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 400 mg tablets
Trial: NCT00522509
Drug: Floxuridine FUDR
RxNorm normalized name: Floxuridine
DrugBank: Floxuridine (DB00322)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00983905
Drug: Theophylline
RxNorm normalized name: Theophylline
DrugBank: Theophylline (DB00277)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: single doses of 300 mg (80 mg/15 ml elixer) administered alone at 7:45 am on Day 1 and then along with colchicine at 7:45 am on Day 19
Trial: NCT00184197
Drug: Placebos
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00280683
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo tablets that match the L-arginine intervention tablets will be given for three months
Trial: NCT02875834
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Suspension administered orally placebo once daily for 28 days after the first 48-hour open label initial phase.
Trial: NCT00487318
Drug: standard of care
FDA approved: no
EMA approved: no
PMDA approved: no
Description: peginterferon/RBV
Trial: NCT00487318
Drug: fluvastatin
RxNorm normalized name: Fluvastatin
DrugBank: Fluvastatin (DB01095)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Add fluvastatin at 20-40 mg/day to standard of care
Trial: NCT00489645
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo SC during euglycemia
Trial: NCT00489645
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo during hyperglycemia
Trial: NCT01812265
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single Dose
Trial: NCT00863798
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching placebo tablets (10 or 50mg). Daily dosing for 10 +/- 4 days during a placebo lead-in period, and then 8 weeks during the double-blind period.
Trial: NCT02866071
Drug: Placebo-Comparator
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50mg IN Placebo
Trial: NCT03545373
Drug: Azithromycin
RxNorm normalized name: Azithromycin
DrugBank: Azithromycin (DB00207)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Azithromycin tablet taken orally
Trial: NCT02941848
Drug: HCP1306
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02019875
Drug: Clarithromycin
RxNorm normalized name: Clarithromycin
DrugBank: Clarithromycin (DB01211)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: CYP3A4 and Pgp inhibitor in both intestine and liiver
Trial: NCT02188849
Drug: Creatine
RxNorm normalized name: Creatine
DrugBank: Creatine (DB00148)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Creatine powder 5 g day
Trial: NCT01377792
Drug: Hypertonic saline
RxNorm normalized name: ENTSOL Hypertonic Saline Nasal Gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: comparison of different dosages of drug
Trial: NCT00591123
Drug: FOLFOX
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Once every two weeks all patients will receive Oxaliplatin 85 mg/m2 IV, Leucovorin 400 mg/m2 IV and 5-FU 400 mg/m2 IV infusions
Trial: NCT04485299
Drug: Bifluorid 10 ,VOCO
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NaF and CaF 10 %
Trial: NCT05229029
Drug: TCM Formula
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TCM herbs：White peony 10g, angelica 10g, Astragalus 20g, Atractylodes macrocephala 10g, tangerine peel 6g, Poria cocos 10g, raw land 10g, cinnamon 3g, Polygala tenuifolia 6g, Schisandra chinensis 6g, raw licorice 6g.
Trial: NCT05229029
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mainly made of dextrin and caramel, containing 1/30 concentration of experimental group drugs